ABOUT US
Research and Development Team


Research and Development TEAM
Michael J. McConnell, MD, PhD.
Chief Scientific Officer, Founder
Antonio González López, MD, PhD, MPH.
Chief Medical Officer
Vaccine Development Manager
Ana I. Rodríguez-Rosado , PhD.
Vaccine Development Manager
Vaccine Development Manager
Scientific Advisor
Senior Vaccine Researcher
Senior Vaccine Researcher
Senior Vaccine Researcher
Senior Vaccine Researcher
Gustavo A. Sánchez Corrales, PhD.
Mass Spectrometry Specialist
Research Technician
Junior Researcher and Project Manager
R&D Project Management Technician
CURRICULUM

Dr. McConnell is a medical doctor from the University of Michigan, biochemistry graduate from the University of Notre Dame, and Ph.D. in microbiology and Immunology from the University of Michigan. He founded Vaxdyn in 2011 while researching on vaccines and immunotherapies against antibiotic-resistant bacteria at the Institute of Biomedicine of Seville. Since 2018, Dr. McConnell is a principal investigator at the Unit of Nosocomial Infections at the National Center for Microbiology (CNM) of the Institute of Health Carlos III of Spain in Madrid. He has led more than 20 research projects in bacteriology, published more than 50 articles in peer-reviewed international journals and filed 7 patents.

Antonio González López, MD, PhD, MPH has nearly 30 years of experience in vaccine clinical development, spanning early-stage research through regulatory approval. He has held senior leadership roles at major organizations including AstraZeneca, GSK, Novartis, Sabin Vaccine Institute, and Gates Medical Research Institute, with a track record across diverse vaccine programs (COVID-19, RSV, Ebola, Marburg, influenza, and HPV). His core expertise lies in clinical development strategy, trial design and execution, IND/regulatory submissions to agencies such as EMA, MHRA, and FDA, and cross-functional team leadership.

Dr. Lugo obtained her Ph.D. in Molecular Biology and Fundamental Pharmacology from the University of Montpellier (France). She is a biochemistry graduate from the Complutense University of Madrid (Spain), and a certified professional in Clinical Research Conduct and Management from the University of California, Berkeley, CA (USA). She joined the Pharma industry sector in 2015, where she specialized in the conduct of early-phase clinical trials, serving as Global Study Associate Director at AstraZeneca. In 2023, she joined Vaxdyn as Head of Project Management to coordinate clinical research on vaccine development.

Dr. Rodríguez-Rosado is a microbiologist with broad experience in protein expression in yeast and Gram-negative bacteria. Her previous work focused on the evolution of Gram-negative bacterial toward antibiotic resistance. She earned an M.Sc. in Pharmaceutical Biotechnology from IUCT Barcelona (Inkemia Group) in 2011 and received her Ph.D. from University of Seville in 2019. In 2019, she joined Vaxdyn to coordinate research on vaccine development.

Dr. Alonso is a bacteriologist with expertise in the ecology and evolution of antibiotic-resistant enterobacteria, her earlier work delved into plasmid-mediated carbapenem resistance in Klebsiella. She earned her M.Sc. in Microbiology Applied to Public Health and Infectious Diseases Research from University of Alcalá in 2016 and completed her Ph.D. at the Complutense University of Madrid in 2023. She has conducted research at both the National Centre for Biotechnology (CNB-CSIC) in Madrid, Spain, and the Institut Pasteur in Paris, France. In 2023, she joined Vaxdyn to oversee and bolster research in vaccine development.

Dr. Pérez-Gómez is an international research reference in clinical microbiology and infectious diseases, with 50 publications cited 954 times (H index 16), 2 patents, and participation in 30 international conferences. Her previous work focused on studying the molecular basis of antimicrobial resistance and vaccine development. Before joining Vaxdyn in 2021 as lead scientist for delivering novel vaccine candidates based on Vaxdyn’s technology, she conducted research at the Institute of Biomedical Research of A Coruña, Spain and at Miami University (Oxford, OH, USA).

Dr. Cordero is a bacteriologist with an extensive expertise in Outer Membrane Proteins (OMPs) expression in Gram-negative bacteria. She joined Vaxdyn in 2020 to support research in the lead development of KapaVax. She earned her Ph.D. from the University of Seville and completed postdoctoral work at National Centre for Biotechnology (CNB-CSIC), in Madrid, Spain.

Dr. García holds a degree in Biochemistry from the University of Castilla-La Mancha and a Ph.D. in Microbiology and Parasitology from the Complutense University of Madrid. She has extensive experience in microbiology and molecular biology, having conducted research at renowned institutions such as the National Center for Microbiology, where she focused her work on bacterial genetics, and Rovira i Virgili University, where she studied antifungal resistance mechanisms in yeast. In 2023, she joined Vaxdyn’s technical team, where she contributes to the development of new vaccines and the execution of in vivo trials, applying her scientific expertise to support innovative solutions in the biomedical field.

Dr. Del Pozo holds a degree in Biotechnology and a Ph.D. in Biology from the Universidad Autónoma de Madrid, with a strong research background in epigenetics, molecular biology, and microbiology. She has conducted research at institutions such as IMDEA-Food and the National Centre for Microbiology (CNM-ISCIII), contributing to projects on extracellular vesicles, microRNAs, and the development of vaccines targeting multidrug-resistant bacteria. In 2024, she joined Vaxdyn where she contributes to the development of innovative vaccines by leading in vivo trials.

Dr. Cano is a pharmacist and PhD in Biomedical Sciences, specializing in antimicrobial resistance and the development of innovative vaccines against multidrug-resistant bacterial pathogens. Her expertise encompasses bacterial outer membrane biology, host–pathogen interactions, and the design and evaluation of outer membrane vesicle-based vaccines. In 2026, she joined Vaxdyn as a Research Scientist, contributing to preclinical in vivo studies, and the characterization and evaluation of vaccine candidates, supporting their progression towards clinical development.

Dr. Sánchez holds a Ph.D. in Biochemistry from the Universidad Autónoma de Barcelona (UAB), with a strong specialization in the application of mass spectrometry techniques to support the development of biopharmaceuticals. He also holds a degree in Biology from the Universidad de Alicante and a postgraduate specialization in Pharmaceutical Quality from the Universidad de Barcelona. He is currently working at Vaxdyn, where he develops and implements innovative analytical methods specifically adapted to the challenges of vaccine development.

Ms. Ramiro is a Senior Technician in Pathological Anatomy and Cytology with broad experience in molecular biology. She worked at CBM-CSIC in the immune and inflammatory diseases group. In 2019, she joined the La Paz Hospital Research Institute, where she worked with the allergic diseases group, specializing in the search and identification of allergens, and later with the gynecology group, researching biomarkers of maternal-fetal diseases. In 2024, she joined Vaxdyn as a research technician.

Ms. Sánchez holds a B.Sc. in Biotechnology from Pablo de Olavide University and gained early research experience at the Andalusian Centre for Developmental Biology (CABD), working on projects studying early zebrafish development and the use of CRISPR-Cas systems. She also holds a Master’s in Advanced Studies in Business Administration from the University of Seville. She joined Vaxdyn in 2025, where she combines her scientific background with project coordination, communication, and organizational development to support innovative vaccine projects against multidrug-resistant bacteria.

Ms. Pérez is an accountant specializing in the financial management of R&D activities. She holds a B.S. degree in Finance and Accounting from the Universidad Pablo de Olavide (Seville, Spain). She joined Vaxdyn in 2026, where she contributes to the financial and administrative coordination of the company’s research activities, contributing to accounting processes, funding administration, tax compliance, and financial control.
CONTACT
Vaxdyn
Supported by







